Literature DB >> 1328733

The role of mu- and kappa-opioid receptors in cocaine-induced conditioned place preference.

T Suzuki1, Y Shiozaki, Y Masukawa, M Misawa, H Nagase.   

Abstract

Effects of buprenorphine, U-50,488H, naltrexone and lithium chloride on cocaine conditioned place preference were examined. Buprenorphine, a mixed opioid agonist-antagonist, blocked the cocaine-induced place preference. Furthermore, the kappa-receptor agonist U-50,488H and the mu-receptor antagonist naltrexone both antagonized the cocaine preference. U-50,488H or naltrexone alone induced a place aversion in a dose-dependent manner. However, the cocaine-induced conditioned place preference was not blocked by lithium chloride, although the latter induced a conditioned place aversion, indicating that the antagonism of cocaine-induced place preference by U-50,488H or naltrexone does not result from a functional antagonism. These results suggest that mu- and kappa-opioid receptors may be involved in cocaine-induced conditioned place preference.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1328733     DOI: 10.1254/jjp.58.435

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  47 in total

1.  Interactions between opioids and cocaine on locomotor activity in rats: influence of an opioid's relative efficacy at the mu receptor.

Authors:  Mark A Smith; Keith A Gordon; Christopher K Craig; Paul A Bryant; M Eric Ferguson; Adam M French; Jason D Gray; Jacob M McClean; Jonathan C Tetirick
Journal:  Psychopharmacology (Berl)       Date:  2003-04-01       Impact factor: 4.530

2.  Acute withdrawal from chronic escalating-dose binge cocaine administration alters kappa opioid receptor stimulation of [35S] guanosine 5'-O-[gamma-thio]triphosphate acid binding in the rat ventral tegmental area.

Authors:  A P Piras; Y Zhou; S D Schlussman; A Ho; M J Kreek
Journal:  Neuroscience       Date:  2010-05-07       Impact factor: 3.590

3.  Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice.

Authors:  Yong Zhang; Eduardo R Butelman; Stefan D Schlussman; Ann Ho; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

Review 4.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

Review 5.  The role of kappa-opioid receptor activation in mediating antinociception and addiction.

Authors:  Yu-hua Wang; Jian-feng Sun; Yi-min Tao; Zhi-qiang Chi; Jing-gen Liu
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

6.  Role of Long Noncoding RNA Gas5 in Cocaine Action.

Authors:  Haiyang Xu; Amber N Brown; Nicholas J Waddell; Xiaochuan Liu; Graham J Kaplan; Javed M Chitaman; Victoria Stockman; Rachel L Hedinger; Ryan Adams; Kristen Abreu; Li Shen; Rachael Neve; Zuoxin Wang; Eric J Nestler; Jian Feng
Journal:  Biol Psychiatry       Date:  2020-05-11       Impact factor: 13.382

7.  Neuropharmacological characterization of local ibogaine effects on dopamine release.

Authors:  M S Reid; K Hsu; K H Souza; P A Broderick; S P Berger
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

8.  The macrocyclic peptide natural product CJ-15,208 is orally active and prevents reinstatement of extinguished cocaine-seeking behavior.

Authors:  Jane V Aldrich; Sanjeewa N Senadheera; Nicolette C Ross; Michelle L Ganno; Shainnel O Eans; Jay P McLaughlin
Journal:  J Nat Prod       Date:  2013-01-17       Impact factor: 4.050

9.  Kappa Opioid Receptor-Mediated Disruption of Novel Object Recognition: Relevance for Psychostimulant Treatment.

Authors:  Jason J Paris; Kate J Reilley; Jay P McLaughlin
Journal:  J Addict Res Ther       Date:  2011-12-24

10.  Cocaine place conditioning increases pro-opiomelanocortin gene expression in rat hypothalamus.

Authors:  Y Zhou; A Kruyer; A Ho; M J Kreek
Journal:  Neurosci Lett       Date:  2012-10-13       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.